Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04877691 · ClinicalTrials.gov registry record · Phase 3
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT04877691 is a Phase 3 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 367 participants, roughly in line with the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT04877691, a Phase 3 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Medi-546
Study Locations (20)
California
- Research Site - El Cajon
- Research Site - Fullerton
- Research Site - Hemet
- Research Site - La Mesa
- Research Site - Los Angeles
- Research Site - Menifee
- Research Site - Upland
Florida
- Research Site - Brandon
- Research Site - Clearwater
- Research Site - Clearwater
- Research Site - Miami
- Research Site - Tampa
- Research Site - Tampa
Arizona
- Research Site - Paradise Valley
- Research Site - Phoenix
Michigan
- Research Site - Flint
- Research Site - Lansing
Alabama
- Research Site - Birmingham
Colorado
- Research Site - Aurora
Idaho
- Research Site - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2026-11-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04877691
The ClinicalTrials.gov registry entry for NCT04877691 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04877691 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04877691 about?
NCT04877691 is a clinical study titled "Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus". The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
What is the current status of trial NCT04877691?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2021-06-08. Estimated completion is 2026-11-06.
What conditions does trial NCT04877691 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT04877691?
The interventions under investigation include: Placebo (DRUG), Medi-546 (DRUG).
Who is sponsoring clinical trial NCT04877691?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04877691 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.